IPO registrations (S-1, F-1) · Registrants
Evolus, Inc.
- SEC CIK
- 1570562 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2018-01-09, last 2018-07-16; 2 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2018-02-09; declared effective 2018-02-07
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 520 NEWPORT CENTER DRIVE, SUITE 1200, Newport Beach, CA 92660
- EIN
- 46-1385614
- Ticker
- EOLS (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Evolus, Inc. on the corporate pages
Offering terms
- Proposed price range
- $12.00–$14.00 per share (S-1/A filed 2018-02-01)
- Final price
- $12.00 per share, within the range (424B4 filed 2018-02-09, an initial public offering)
- Shares sold
- 5,000,000
- Gross proceeds
- $60,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol EOLS
- Lead underwriters
- Cantor Fitzgerald (2,000,000 shares); Mizuho (1,250,000 shares)
- Syndicate
- Truist Securities (875,000); JMP Securities (875,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: EVOLUS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: Evolus, Inc. Fuzzy (name and state)
- Business registration: EVOLUS INC. Fuzzy (name and state)
- Business registration: EVOLUS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: EVOLUS, INC. EXACT (EIN (EXACT))
- Form D issuer: Evolus, Inc. EXACT (CIK (EXACT))
- Lobbying client: EVOLUS INC Fuzzy (name and state)
- SEC filer: Evolus, Inc. EXACT (CIK (EXACT))
Filings 12
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2018-01-09 | S-1 | S-1 (registration) | Evolus, Inc. | 0001570562-18-000008 ↗ |
| 2018-01-25 | S-1/A | S-1/A (amendment) | Evolus, Inc. | 0001628280-18-000572 ↗ |
| 2018-01-29 | S-1/A | S-1/A (amendment) | Evolus, Inc. | 0001628280-18-000644 ↗ |
| 2018-02-01 | S-1/A | S-1/A (amendment) | Evolus, Inc. | 0001628280-18-000839 ↗ |
| 2018-02-07 | EFFECT | EFFECT (declared effective) | Evolus, Inc. | 9999999995-18-000356 ↗ |
| 2018-02-09 | 424B4 | 424B4 (final prospectus) | Evolus, Inc. | 0001628280-18-001336 ↗ |
| 2018-07-16 | S-1 | S-1 (registration) | Evolus, Inc. | 0001570562-18-000078 ↗ |
| 2018-07-18 | EFFECT | EFFECT (declared effective) | Evolus, Inc. | 9999999995-18-001830 ↗ |
| 2018-07-20 | 424B4 | 424B4 (final prospectus) | Evolus, Inc. | 0001570562-18-000090 ↗ |
| 2019-04-15 | EFFECT | EFFECT (declared effective) | Evolus, Inc. | 9999999995-19-000710 ↗ |
| 2019-05-15 | 424B4 | 424B4 (final prospectus) | Evolus, Inc. | 0001570562-19-000080 ↗ |
| 2019-05-17 | 424B4 | 424B4 (final prospectus) | Evolus, Inc. | 0001570562-19-000082 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-02-01 | S-1/A | registration statement | $12.00–$14.00 | 5,000,000 | - | Nasdaq EOLS | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2018-02-09 | 424B4 | final prospectus | $12.00 | 5,000,000 | $60,000,000 | Nasdaq EOLS | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| AEON Biopharma, Inc. | Other; TenPercentOwner | 9 | 2018–2020 | ||
| Avelar Rui | Officer | Chief Medical Officer; See Remarks | 26 | 2018–2026 | |
| BLANK SIMONE | Director | 13 | 2018–2025 | ||
| Hau Bosun | Director | 6 | 2018–2020 | ||
| HAYMAN ROBERT | Director | 12 | 2018–2024 | ||
| Malik Vikram | Director | 20 | 2018–2026 | ||
| MARMO J CHRISTOPHER | Officer | Chief Operating Officer | 1 | 2018 | |
| Romine Kristine | Director | 11 | 2018–2020 | ||
| Simhambhatla Murthy V | Director,Officer | See Remarks | 1 | 2018 | |
| GILL DAVID N | Director | 14 | 2018–2026 | ||
| MOATAZEDI DAVID | Director,Officer | See Remarks | 38 | 2018–2026 | |
| SILVERNAIL LAUREN P | Officer | See Remarks | 13 | 2018–2022 | |
| Jafar Michael M. | Officer | Chief Marketing Officer; See Remarks | 9 | 2018–2021 | |
| FARRELL PETER C | Director | 7 | 2019–2023 | ||
| Parschauer Karah Herdman | Director | 11 | 2019–2026 | ||
| Alphaeon 1 LLC | TenPercentOwner | 3 | 2020–2023 | ||
| Medytox Inc. | Other; TenPercentOwner | 16 | 2021–2023 | ||
| Muilenburg Crystal | Officer | Chief Marketing Officer | 6 | 2021–2022 | |
| Stewart Brady | Director | 7 | 2022–2026 | ||
| Beaver Sandra | Officer | Chief Financial Officer | 14 | 2022–2025 | |
| Yamagishi-Dressler Tomoko | Officer | Chief Marketing Officer | 7 | 2023–2025 | |
| White Albert G III | Director | 5 | 2024–2026 | ||
| Mitchell Tatjana | Officer | Chief Financial Officer | 3 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-07-17 | Evolus, Inc. | Pharmaceuticals | $40,000,000 | $40,000,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | EVOLUS, INC. | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Evolus, Inc. | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | Evolus, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | Evolus, Inc. | State business registries | name and state | |
| Business registration | EVOLUS INC. | State business registries | name and state | |
| Business registration | EVOLUS, INC. | State business registries | EIN (EXACT, as the state registration reports it) | |
| Business registration | EVOLUS, INC. | State business registries | name and state | |
| Form 5500 plan sponsor | EVOLUS, INC. | EIN (EXACT) | ||
| Lobbying client | EVOLUS INC | Federal lobbying (LDA) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CA first:
- CONNETICS CORP CA
- SIBIA NEUROSCIENCES INC CA
- MEDIVATION, INC. CA
- IMMUSOL INC CA
- DYNAVAX TECHNOLOGIES CORP CA
- RIGEL PHARMACEUTICALS INC CA
- Diadexus, Inc. CA
- CymaBay Therapeutics, Inc. CA
- CRESCENDO PHARMACEUTICALS CORP CA
- SPIROS DEVELOPMENT CORP II INC CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health